Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750366 | 0.85 | POLB (0.43) | SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL11379564 | 0.82 | KMT2A (0.40) | SMN1; SMN2KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL11549019 | 0.80 | HPGD (0.49) | SMN1; SMN2KMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL4994054 | 0.78 | POLB (0.43) | KMT2AL3MBTL1MEN1NPC1RAB9A | |
| SCHEMBL22763891 | 0.78 | KMT2A (0.48) | SMN1; SMN2KMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL7353467 | 0.77 | HPGD (0.60) | SMN1; SMN2KMT2AMEN1RAB9APOLB | |
| SCHEMBL236205 | 0.76 | HPGD (0.56) | SMN1; SMN2KMT2AL3MBTL1MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL27610313 | 0.75 | HPGD (0.54) | SMN1; SMN2KMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL5045391 | 0.74 | HPGD (0.53) | SMN1; SMN2KMT2AL3MBTL1MEN1NPC1 | |
| Acetone SCHEMBL29448975 | 0.73 | HPGD (0.53) | SMN1; SMN2KMT2AL3MBTL1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6747054-B2 | FOR THERAPY OF LOW BONE MASS, PARTICULARLY OSTEOPOROSIS, FRAILTY, AN OSTEOPOROTIC FRACTURE, A BONE DEFECT, CHILDHOOD IDIOPATHIC BONE LOSS, ALVEOLAR BONE LOSS, MANDIBULAR BONE LOSS, BONE FRACTURE, OSTEOTOMY | PFIZER INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | CAMERON KIMBERLY O (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003077910-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1339678-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-4143051-A | GREATER TISSUE SPECIFICITY OF ACTION | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4113723-A | TISSUE SPECIFICITY | PFIZER INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4102894-A | TISSUE SPECIFICITY | PFIZER INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4080368-A | PROSTAGLANDINS | PFIZER INC. (US) | 1978-03-21 | — | — | US | disclosed |
| US-3980642-A | 15-Substitute D-ω-pentanorprostaglandins | PFIZER INC. (US) | 1976-09-14 | — | — | US | disclosed |
| US-3956284-A | INCREASED TISSUE SPECIFITY OF ACTION | PFIZER INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 3322/4885KMT2A 3662/4885L3MBTL1 3097/4885 |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 4305/4885KMT2A 2494/4885L3MBTL1 1708/4885 |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 4192/4885KMT2A 2280/4885L3MBTL1 1768/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 4192/4885KMT2A 2280/4885L3MBTL1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.